CLOs on the Move

Intellia Therapeutics

www.intelliatx.com

 
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Kristin Creed
Director of Legal Operations Profile
Nishla Keiser
SVP, Deputy General Counsel Profile
Nishla Keiser
Senior Vice President and Deputy General Counsel Profile
Mary Ferguson
Vice President, Head of Intellectual Property Profile
Jose Rivera
EVP, General Counsel and Corporate Secretary Profile

Similar Companies

Pronutria

Amino acid biology is fundamental to life, regulating biological pathways critical to health. A variety of conditions occur when amino acid pathways become dysregulated.

Owlstone Medical

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive early detection and precision medicine for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.

Center for Functional Genomics

Center for Functional Genomics is a Rensselaer, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Keros Therapeutics

Keros Therapeutics is dedicated to the discovery and development of novel therapeutics for neuromuscular diseases

Loyal

Loyal is part of Cellular Longevity, a company working to develop the first drugs explicitly intended to extend healthspan and lifespan — first in dogs, and then in humans, too. By quantifying and controlling the mechanisms of aging, we hope to delay the onset and reduce the severity of age-related diseases, which means more, healthier years for both species. At Loyal, our first products to market are focused on longevity and healthspan in dogs. Join us in our mission to help dogs everywhere.